IVD False Positives: Sample Carryover or Open-Amplification Contamination?
Separate automated sample carryover from open-amplification contamination in molecular IVDs, then select studies, controls and corrective actions within the evidence limits.
Occasional false positives in a molecular in-vitro diagnostic (IVD) workflow call for a defined investigation. First distinguish residual specimen or target nucleic acid transferred during automated sample processing from previously amplified product introduced during open amplification and detection work. Then select a challenge study and controls that actually traverse the suspected route. Changing a wash procedure or discarding reagents before identifying the affected stage can leave the original question unanswered.
Two contamination paths, with overlapping symptoms
This article uses Path A for sample-path carryover and Path B for open-amplification amplicon contamination. These are practical investigation categories, not a formal regulatory division. The literature also uses carryover for contamination by earlier polymerase chain reaction (PCR) products. Both paths can involve droplets, surfaces or equipment, and both can coexist. False-positive results can also arise from causes outside these two paths, including nonspecific assay signals.
Path A asks whether material from one specimen or processing position reaches another through the instrument or automated extraction workflow. Relevant evidence includes processing order, shared handling steps and neighboring well positions.
Path B asks whether products from an earlier amplification enter a later reaction through open handling, contaminated reagents, equipment or the laboratory environment. Relevant evidence includes reaction setup, post-amplification activities and environmental monitoring.
A signal pattern is a hypothesis generator. A neighboring positive well does not by itself identify splashing, and a positive no-template control does not by itself establish that the contaminant is an amplicon.
The study examples come from FDA’s respiratory viral panel (RVP) guidance issued October 9, 2009, and enterovirus RNA assay guidance issued January 2, 2009. Their scopes are respiratory viral panel multiplex nucleic acid assays and enterovirus RNA assays in cerebrospinal fluid, respectively. Their recommended approaches permit alternatives that provide equivalent assurances of safety and effectiveness. They are not newly issued rules or a universal protocol for all molecular IVDs.
Path A: challenge the automated sample and extraction route
For multi-sample assays and devices requiring instrumentation, RVP Section 6.B.vi and enterovirus Section 6.C.4 describe alternating high-positive and high-negative samples. The arrangement depends on the device’s operation. This makes the processing map part of the evidence: a plate diagram without the actual handling order may leave the suspected transfer opportunity untested.
Run series: both guidances recommend at least five runs with alternating high-positive and high-negative samples. This is a recommendation in the cited device-specific guidance, not a universal statutory run count.
High-positive challenge: the sample should be high enough to exceed 95% or more of results from diseased-patient specimens in the intended-use population. Document the basis for the selected level rather than substituting an arbitrary concentrated stock.
High-negative challenge: the analyte concentration is below the cutoff and gives negative results approximately 95% of the time on repeat testing. It is not automatically interchangeable with a sample containing no analyte.
Effect estimate: compare the percentage of negative high-negative results in the carryover study with the 95% reference described in the guidance. Do not interpret every positive high-negative result as proof of transfer or invent a universal pass percentage.
RVP Section 6.A.iv addresses a different arrangement: potential well-to-well cross-contamination during automated extraction. It describes an extraction validation grid with a nucleic-acid-containing sample at the highest anticipated clinical level surrounded on all sides by no-template controls. The section also calls for a software hazard analysis for automated extraction systems as part of the submission. It does not prescribe an exhaustive list of robot fault modes or mechanical repairs.
In applying these examples, explain which route each layout challenges. A sequence that places a negative sample after a positive challenges a processing-order relationship; a grid challenges relationships between neighboring positions during extraction. Neither geometry automatically covers the other. This is an interpretation of the study designs, and the appropriate combination depends on the device configuration and the claimed extraction method.
Path B: track amplified product through open work
The APHL molecular workflow resource describes how opening amplified-product tubes or pipetting their contents can disperse amplification products. Its operational setting is newborn-screening molecular laboratories, not a device-specific FDA submission requirement. The transferable lesson is to map where amplification products are exposed and which people, equipment or materials can return from those activities to reaction preparation.
In his 2004 review of PCR carryover contamination, Aslanzadeh describes PCR yields reaching approximately 10^9 target copies and aerosols containing as many as 10^6 amplification products. These are historical scale illustrations, not measured contamination loads in the reader’s laboratory. The review describes buildup on reagents, equipment and ventilation systems; it does not establish an indefinite persistence time or a universal airborne duration.
The practical investigation question is where an earlier amplification product could re-enter a new reaction. Record open post-amplification steps alongside reagent preparation and sample addition. Do not classify an event solely by whether it occurs inside an instrument or on a bench: contaminating amplified product can reach equipment, and sample material can contaminate an open workflow.
The two-path mechanism and control-verification matrix
This matrix synthesizes the cited study designs and control purposes into an investigation aid. The signal-pattern row contains synthetic illustrations, not laboratory observations or diagnostic rules. Corrective-action entries identify investigation directions, not validated repair instructions for a particular instrument.
| Decision field | Path A: automated sample-path carryover | Path B: open-amplification contamination |
|---|---|---|
| Mechanism to investigate | Specimen or target nucleic acid transferred between sample positions during shared handling or extraction. | Earlier amplification product introduced into later reactions through open handling, materials or the environment. |
| Illustrative signal pattern — synthetic | Negative-position signals appear after a high-positive sample or near a positive extraction well; investigate order and position associations. | No-template controls or negative samples show signals across different positions; investigate setup and environmental routes. Neither pattern is specific. |
| Demonstrating study or investigation evidence | The 2009 FDA alternating series: at least five runs; high positive above 95% or more of intended-population diseased-specimen results; high negative approximately 95% repeat-negative; estimate against 95%. The RVP extraction grid addresses adjacent positions. | Combine reaction-control results with a map of open-product activities and environmental wipe evidence. APHL describes these monitoring approaches; it does not provide an FDA aerosol-challenge submission protocol. |
| Verifying control and placement | Template-free controls placed in the extraction grid or a documented negative process control can interrogate the stages they traverse. | A reaction-only no-template control interrogates reaction components and setup; environmental wipes interrogate sampled surfaces for the tested target. |
| Corrective-action direction | Investigate implicated sample-handling steps, cleaning performance and instrument condition using the manufacturer’s procedures; verify the relevant route after corrective action. | Address implicated reagents, materials and work areas; review separation and movement between pre- and post-amplification activities, then verify with appropriate controls. |
| Interpretation limit | A negative result supports only the tested configuration, challenge and sequence; it does not certify every open-workflow step. | A positive result does not identify the contaminant’s physical origin by itself; a negative wipe does not establish that every surface or future reaction is clean. |
Which controls answer which questions?
Define where the no-template control enters
RVP Section 5.D.i describes a blank or no-template control (NTC) containing buffer or transport medium and assay components without nucleic acid. Its purpose is to assess target contamination or increased amplification background. Importantly, the same guidance places template-free controls in an extraction grid. An NTC is therefore not inherently restricted to the amplification plate: its investigative reach depends on where it enters the workflow.
A reaction-only NTC that bypasses extraction cannot test transfer occurring solely during extraction. A template-free control that undergoes extraction can address that stage, subject to its matrix and layout. For each control, write down its composition, entry point and subsequent operations. Labels such as blank or negative are insufficient if the report does not show which suspected route the material encountered.
Use discordant controls to narrow the stage
As a synthetic example, consider a positive extraction blank alongside a negative reaction-only NTC. That pattern gives a reason to investigate stages traversed by the extraction blank but bypassed by the reaction-only control. It does not prove a contaminated probe or a particular extraction-room source. Differences in matrix, timing and exposure also belong in the comparison. The next investigation should distinguish those possibilities rather than treating the first discordant pair as a root-cause finding.
Likewise, a positive NTC flags a problem requiring interpretation under the assay’s result rules. It can be consistent with contamination of reagents, setup or the environment, but it does not distinguish patient nucleic acid from amplified product merely because no template was deliberately added. Preserve the observed result and the control’s handling history before deciding which path it supports.
Interpret environmental wipes within their coverage
APHL describes routine surface wipe testing and an NTC on each reaction plate as monitoring tools in its workflow context. A wipe result concerns the sampled area and tested target. The resource does not establish a universal monthly interval, fixed swab area or advance-warning period. Set sampling coverage through the laboratory’s documented method; record locations and timing so a later comparison has an interpretable basis.
Keep challenge samples distinct from routine blanks
The high-negative material in the alternating FDA study and a template-free process blank answer different questions. The former has a defined low analyte concentration with an expected repeat-testing response; the latter is intended to enter without target. Keep those identities visible in the plate map and result ledger. Combining their results under a single negative-control heading obscures the reference used to estimate the challenge effect.
Why a closed system does not end the investigation
Enterovirus guidance Section 5.B presents closed-tube reagent design, including a self-containing cartridge, as a way to minimize false positives from amplicon or carryover contamination. Both FDA guidances also state that an NTC may not be applicable or needed for single-test disposable cartridges or tubes. That boundary does not establish a universal substitute involving factory release testing or a particular internal negative control; those controls require evidence for the actual device.
Aslanzadeh’s 2004 review reports that false positives had occurred in automated systems available at that time despite technical improvements. It is historical counter-evidence to an assumption of immunity, not evidence about every current cartridge platform. A closed format changes which steps are exposed; the investigation still needs to identify the steps and controls that apply.
Match corrective action to the supported route
For a suspected sample-processing route, tie corrective action to the actual instrument and the investigation evidence. Record which handling operation or cleaning function is implicated, what the manufacturer’s procedure permits, and which challenge will test the changed condition. The cited FDA guidance provides study examples, not instructions to increase wash volumes, replace specific valve materials or reprogram robot trajectories.
For an open-workflow route, APHL describes separation of pre- and post-amplification activities, dedicated materials and protective equipment, filter tips or positive-displacement pipettes, and aliquoted reagents. It also describes discarding suspect reagents and decontaminating affected work areas. Apply these practices to the route under investigation rather than assuming a universal requirement for three rooms or specified air pressures.
For reusable items, APHL describes a 10% household-bleach solution followed by a water rinse. This refers to a dilution of household bleach, not a 10% active sodium-hypochlorite concentration. APHL does not establish a single contact time or cleaning recipe for every instrument. Use the applicable compatible, documented decontamination procedure; do not apply a surface-cleaning instruction to patient specimens or assay reaction material.
Aslanzadeh describes reduced UV efficacy for short or G+C-rich templates and possible effects on polymerase and primers. In dUTP/uracil-N-glycosylase (UNG) control, uracil incorporation makes earlier amplification products susceptible to removal; G+C-rich targets and residual UNG activity can complicate performance. Verify the chemistry in the actual assay instead of assuming it removes every nucleic-acid contaminant.
Make the evidence section support a bounded conclusion
A useful report connects the proposed route to the study, the controls and the action taken. The following is an editorial synthesis for documenting an investigation, not a new FDA-required submission template. It can be applied to either path and makes unresolved alternatives visible instead of hiding them behind a general statement that contamination was controlled.
State the hypothesis and alternatives. Identify the suspected material and transfer opportunity, and name the observation that would weaken that explanation. Include the possibility that both paths contribute or that the signal has another cause.
Define the tested configuration. Record the instrument and extraction method, processing order, spatial arrangement, material identities, challenge levels, reagent lots and control entry points relevant to the investigation. Explain how this configuration exposes the suspected route.
Preserve result identities. Keep each sample and control attached to its position, order and original reported result. Separate a target-free blank from a high-negative challenge and an environmental sample. Describe deviations and the rationale for any repeat testing.
Explain the decision rule before drawing the conclusion. Distinguish the source’s recommended comparison from locally justified acceptance criteria. Report the observed results and their limitations rather than treating a guidance number as proof of zero risk.
Connect the corrective action to verification. Describe what changed, which relevant conditions were challenged afterward and what remained untested. A clean result after several simultaneous changes may support recovery without identifying which change removed the original cause.
For example, if order-associated signals disappear after an instrument intervention, the defensible statement concerns the tested order and configuration after that intervention. It does not establish that environmental contamination was absent before the intervention. Conversely, negative wipes after cleaning support the sampled areas and targets; they do not establish sample-path performance under a high-positive challenge. Keeping these conclusions separate helps teams see whether a further experiment answers a remaining question.
If both the extraction controls and reaction-only controls show unexpected signals, a single label such as instrument carryover is premature. Map their shared exposures and decide which comparison can separate them. A report can legitimately conclude that the affected workflow recovered while the exact transfer route remains unresolved. That conclusion is more useful than claiming a precise mechanism that the controls never distinguished.
Document regulatory scope and adjacent decisions
21 CFR 866.3960(b)(2) requires detailed performance-study documentation that includes carryover and cross contamination for nucleic-acid-based devices detecting microbial pathogens directly from whole blood. It names both study categories, but does not define them as Path A and Path B, prescribe separate reports for each, or apply that whole-blood device classification to respiratory panels. Its amendment history includes December 4, 2025. Use the provision within its stated scope.
Supplier qualification remains a separate decision: oligonucleotide supplier qualification addresses material and supplier controls, while enzyme supplier qualification addresses a different input to assay performance. Evidence from either may inform a contamination investigation, but it cannot substitute for testing the relevant transfer route. The analytical performance validation guide addresses broader assay characterization. Here, the decision is narrower: which contamination hypothesis is supported, what experiment can distinguish it, and which conclusion the resulting evidence permits.